StockData
Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc. (EVFM) stock

EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)

Close on Oct 19, 2026Market cap $865.23KP/E –Yield –

Evofem Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Evofem Biosciences's free cash flow for the twelve months ending Jun 30, 2026 was -$477.00K. For fiscal 2025 it was -$2.00M. The highest annual figure on record is -$2.00M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$2.00M–
FY2024Dec 31, 2024-$3.90M–
FY2023Dec 31, 2023-$8.97M–
FY2022Dec 31, 2022-$70.75M–
FY2021Dec 31, 2021-$149.61M–
FY2020Dec 31, 2020-$107.08M–
FY2019Dec 31, 2019-$55.26M–
FY2018Dec 31, 2018-$56.51M–
FY2017Dec 31, 2017-$19.25M–
FY2015Dec 31, 2015-$38.14M–
FY2014Dec 31, 2014-$9.59M–
FY2013Dec 31, 2013-$12.93M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.14M–
Q1 FY2026Mar 31, 2026$2.30M–
Q4 FY2025Dec 31, 2025$28.00K–
Q3 FY2025Sep 30, 2025$336.00K+208.3%
Q4 FY2024Dec 31, 2024-$2.41M–
Q3 FY2024Sep 30, 2024-$459.00K–
Q2 FY2024Jun 30, 2024-$1.14M–
Q1 FY2024Mar 31, 2024$109.00K–
Q2 FY2023Jun 30, 2023-$1.50M–
Q1 FY2023Mar 31, 2023-$4.94M–
Q4 FY2022Dec 31, 2022-$6.57M–
Q3 FY2022Sep 30, 2022-$16.37M–
Q2 FY2022Jun 30, 2022-$26.83M–
Q1 FY2022Mar 31, 2022-$20.99M–
Q4 FY2021Dec 31, 2021-$21.32M–
Q3 FY2021Sep 30, 2021-$37.96M–
Q2 FY2021Jun 30, 2021-$54.91M–
Q1 FY2021Mar 31, 2021-$35.41M–
Q4 FY2020Dec 31, 2020-$40.50M–
Q3 FY2020Sep 30, 2020-$36.12M–
Q2 FY2020Jun 30, 2020-$15.49M–
Q1 FY2020Mar 31, 2020-$14.97M–
Q4 FY2019Dec 31, 2019-$13.59M–
Q4 FY2018Dec 31, 2018-$10.25M–
Q4 FY2017Dec 31, 2017-$4.95M–

More Evofem Biosciences figures

See a number that looks wrong?